Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Research & Development (2016 - 2025)

Historic Research & Development for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $1.3 million.

  • Cumberland Pharmaceuticals' Research & Development fell 403.71% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 1088.54%. This contributed to the annual value of $4.8 million for FY2024, which is 1744.91% down from last year.
  • Cumberland Pharmaceuticals' Research & Development amounted to $1.3 million in Q3 2025, which was down 403.71% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Research & Development ranged from a high of $1.9 million in Q3 2023 and a low of $1.1 million during Q2 2024
  • Its 5-year average for Research & Development is $1.4 million, with a median of $1.4 million in 2021.
  • In the last 5 years, Cumberland Pharmaceuticals' Research & Development skyrocketed by 3879.29% in 2022 and then plummeted by 3721.32% in 2023.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Research & Development stood at $1.6 million in 2021, then fell by 12.83% to $1.4 million in 2022, then dropped by 10.04% to $1.3 million in 2023, then grew by 2.21% to $1.3 million in 2024, then dropped by 3.04% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.5 million for Q2 2025, and $1.3 million during Q1 2025.